List of Excipients in Branded Drug PRUCALOPRIDE SUCCINATE

Generic Drugs Containing PRUCALOPRIDE SUCCINATE

Company	Ingredient	NDC	Excipient
Somerset Therapeutics LLC	prucalopride succinate	70069-821	CELLULOSE, MICROCRYSTALLINE
Somerset Therapeutics LLC	prucalopride succinate	70069-821	HYPROMELLOSE 2910
Somerset Therapeutics LLC	prucalopride succinate	70069-821	LACTOSE MONOHYDRATE
Somerset Therapeutics LLC	prucalopride succinate	70069-821	MAGNESIUM STEARATE
Somerset Therapeutics LLC	prucalopride succinate	70069-821	POLYETHYLENE GLYCOL 4000
Somerset Therapeutics LLC	prucalopride succinate	70069-821	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in PRUCALOPRIDE SUCCINATE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE 2910
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL 4000
1	SILICON DIOXIDE

Last updated: September 24, 2026

Prucalopride succinate is a small-molecule, once-daily 5-HT4 receptor agonist approved for chronic idiopathic constipation. The principal excipient opportunity is not a basic tablet copy. It is a low-dose, high-uniformity formulation platform that improves swallowability, removes lactose, supports pediatric or geriatric use, and creates differentiated products suitable for ANDA or 505(b)(2) strategies. U.S. reference product Motegrity is approved in 1 mg and 2 mg tablets; European product Resolor is also available in 1 mg and 2 mg strengths.[1,2]

Prucalopride Succinate Excipient Strategy and Commercial Opportunities

What is prucalopride succinate used for?

Prucalopride succinate is the succinate salt of prucalopride, a selective serotonin 5-HT4 receptor agonist. It is used to treat chronic idiopathic constipation in adults when laxative therapy has failed to provide adequate relief.

The U.S. Food and Drug Administration approved Motegrity in December 2018 for adults with chronic idiopathic constipation.[1] The European Medicines Agency authorized Resolor for symptomatic treatment of chronic constipation in adults.[2]

Attribute	U.S. Motegrity	European Resolor
Active ingredient	Prucalopride succinate	Prucalopride succinate
Strengths	1 mg, 2 mg	1 mg, 2 mg
Dosage form	Film-coated tablet	Film-coated tablet
Standard adult dose	2 mg once daily	2 mg once daily
Renal impairment dose	1 mg once daily in severe impairment	Dose reduction required in severe renal impairment
Therapeutic area	Chronic idiopathic constipation	Chronic constipation
Regulatory pathway	New drug application	Centralized European authorization
Biosimilar exposure	None	None

Prucalopride is a small molecule, so commercial competition is expected to arise from generic tablets, alternate oral dosage forms, geographic launches, and formulation improvements rather than biosimilar substitution.

What excipients are used in prucalopride succinate tablets?

The U.S. Motegrity label identifies a conventional immediate-release tablet formulation containing lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, and film-coating components.[1] The European product information identifies comparable tablet excipients, including lactose monohydrate and standard compression and coating materials.[2]

The reference formulation indicates that prucalopride succinate does not require a complex delivery system. Its commercial formulation challenges are more likely to involve low-dose uniformity, tablet robustness, dissolution control, and patient acceptability.

Reference excipient functions

Excipient class	Likely function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Supports low-dose tablet manufacture but creates an opportunity for lactose-free products
Microcrystalline cellulose	Filler, dry binder, disintegration support	Useful for direct compression and mechanical strength
Colloidal silicon dioxide	Glidant and flow aid	Important for blend uniformity at low drug loading
Magnesium stearate	Lubricant	Requires control of concentration and mixing time to avoid dissolution effects
Hypromellose or comparable polymer	Film former	Supports appearance, handling, identification, and moisture protection
Titanium dioxide or colorants	Opacifier or color system	Enables strength differentiation and product identification
Plasticizer	Coating flexibility	Reduces film cracking and improves manufacturing robustness

The exact formulation must be confirmed against the current reference-product labeling and applicable product-specific guidance before development or filing.

Which excipient platform is best for a generic prucalopride tablet?

A lactose-free direct-compression platform is the strongest broad commercial option. A formulation based on microcrystalline cellulose, mannitol or dibasic calcium phosphate, crospovidone or croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate can address common patient and manufacturing requirements without introducing unnecessary formulation complexity.

Recommended base formulation

A practical starting platform would include:

• Microcrystalline cellulose as the primary filler and dry binder.
• Mannitol where improved mouthfeel and a lower-lactose positioning are desired.
• Crospovidone or croscarmellose sodium as the superdisintegrant.
• Colloidal silicon dioxide to improve powder flow and content uniformity.
• Magnesium stearate at the lowest level that provides acceptable ejection and tooling protection.
• Hypromellose-based film coating for color, handling, and moisture control.

Prucalopride is administered at a low dose relative to tablet mass. The formulation therefore requires robust segregation control. Geometric dilution, controlled particle-size distribution, pre-blending of the active with part of the filler, and validated lubrication time are more important than maximizing drug loading.

Lactose-free opportunity

The reference product uses lactose. A lactose-free tablet can target:

• Patients with lactose intolerance or lactose avoidance preferences.
• Hospital formularies seeking simplified excipient profiles.
• International markets with labeling or procurement preferences for lactose-free products.
• Private-label and pharmacy products differentiated by excipient composition.

A lactose-free version is unlikely to receive broad regulatory exclusivity solely because lactose is replaced. Its value lies in market positioning, procurement access, and potential use in a 505(b)(2) product if the dosage form or clinical use is materially changed.

What formulation patents could protect prucalopride products?

Formulation protection could cover the composition, manufacturing process, particle engineering, dissolution profile, or alternate oral dosage form. A conventional immediate-release tablet using routine excipients generally has weaker patent prospects than a formulation with a demonstrated technical effect.

Potential patent claim categories include:

1. A lactose-free prucalopride succinate tablet with defined content-uniformity and dissolution parameters.
2. A direct-compression composition with controlled particle-size distribution.
3. A taste-masked orally disintegrating tablet.
4. A multiparticulate granule or sprinkle formulation.
5. A liquid suspension with defined chemical and microbial stability.
6. A co-processed excipient system that improves low-dose blend uniformity.
7. A moisture-protective coating that improves long-term stability.
8. A formulation that reduces food-effect variability or enables administration with soft food.
9. A pediatric dosage form with age-appropriate dosing flexibility.
10. A manufacturing process that reduces segregation, degradation, or tablet weight variability.

Patent strength depends on whether the formulation produces a measurable benefit over routine substitution. Claims limited to replacing lactose with mannitol, for example, may face obviousness challenges unless supported by unexpected stability, dissolution, manufacturability, or clinical advantages.

When does prucalopride lose exclusivity?

U.S. regulatory exclusivity for Motegrity was based primarily on the five-year new chemical entity period associated with the 2018 approval. That period would have ended in December 2023, subject to statutory calculations and any applicable pediatric extension.[1,3]

Patent expiry is separate from FDA regulatory exclusivity. A generic applicant may file an ANDA after the relevant exclusivity barrier expires, but commercial launch depends on listed patents, Paragraph IV certifications, litigation, settlements, and any remaining enforceable claims.

Exclusivity issue	Commercial effect
Five-year NCE exclusivity	Delayed ANDA filing during the protected period
Three-year clinical investigation exclusivity	Usually less relevant if approval relied on previously established active-ingredient data
Pediatric extension	Can add six months to qualifying exclusivity periods
Listed drug patents	May delay approval or create litigation exposure
Formulation patents	Can delay or narrow specific product launches
Method-of-use patents	May affect labeling, carve-outs, and induced-infringement risk

A current Orange Book review is required to identify the exact listed patent numbers, expiration dates, and any pediatric adjustments. FDA’s Orange Book remains the governing source for U.S. listed patents and exclusivity status.[3]

What is the Orange Book status of Motegrity?

Motegrity is an FDA-approved small-molecule prescription drug. Its U.S. competitive pathway is an ANDA for an equivalent immediate-release tablet, unless a developer pursues a materially different dosage form or clinical positioning through a 505(b)(2) application.

The key Orange Book issues are:

• Whether any patents are currently listed for the approved tablet.
• Whether those patents cover the active ingredient, dosage form, formulation, or method of use.
• Whether a generic applicant can use a Paragraph IV certification.
• Whether any patent litigation triggers a 30-month stay.
• Whether an authorized generic or settlement restricts the timing of competition.

An ANDA applicant must address each listed patent through the applicable certification. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed. If the patent holder brings suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to court action and statutory exceptions.[4]

Which companies are likely to challenge prucalopride?

The likely challengers are large generic companies with gastrointestinal portfolios, established tablet manufacturing capacity, and experience with low-dose oral products. Potential participants include Teva, Viatris, Sandoz, Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and specialist generic manufacturers.

The commercial attractiveness of an ANDA depends on:

• Size of the U.S. chronic constipation market.
• Number of approved generic applicants.
• Whether the reference product has meaningful payer preference.
• Manufacturing cost at low tablet strengths.
• Patent litigation expense.
• Availability of authorized generic supply.
• Ability to launch at risk after a Paragraph IV challenge.
• Retail and specialty-pharmacy channel access.

Because prucalopride is a differentiated prescription prokinetic rather than a commodity osmotic laxative, generic pricing may remain above older over-the-counter constipation products. The addressable market is therefore based on prescription treatment positioning, not only tablet volume.

What are the commercial opportunities for prucalopride excipient innovation?

Lactose-free tablets

This is the most accessible opportunity. A lactose-free tablet can preserve the established immediate-release profile while creating a formulary and patient-facing distinction. The commercial advantage is strongest where the product can be supplied as a private-label generic or where pharmacy substitution does not eliminate the excipient distinction.

Orally disintegrating tablets

An orally disintegrating tablet could address patients with dysphagia, older adults, and patients who have difficulty taking conventional tablets. A taste-masking system would be essential because prucalopride salts may produce an unacceptable oral taste.

Potential excipients include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, sucralose, acesulfame potassium, flavoring agents, and polymeric taste-maskers. The formulation must maintain rapid disintegration without compromising dose uniformity or stability.

An ODT would more likely support a 505(b)(2) strategy than a standard ANDA if the dosage form, labeling, or clinical bridging requirements differ materially from the reference product.

Pediatric liquid or sprinkle formulation

Prucalopride is approved for adults in the United States. A pediatric formulation could target chronic constipation in younger patients if clinical development and regulatory requirements support the indication.

Useful approaches include:

• Ready-to-use oral suspension.
• Dry powder for reconstitution.
• Sachets containing multiparticulate granules.
• Sprinkle capsules or granules administered with soft food.

Key technical barriers are dose measurement, suspension uniformity, palatability, preservative efficacy, chemical stability, and control of sedimentation. A pediatric product can support patent claims if the excipient system provides a defined stability or dosing advantage.

Geriatric and polypharmacy positioning

Older patients frequently use multiple medications and may have swallowing limitations. A small, low-weight, lactose-free, low-sodium tablet or ODT could improve product acceptability. Packaging is also relevant: unit-dose blisters, large-print labeling, and easy-open but senior-friendly packaging may improve adherence without requiring a new pharmaceutical composition.

Global formulation platform

A single lactose-free platform can support markets where lactose labeling, dietary restrictions, or local procurement standards reduce acceptance of the reference composition. Excipients should be selected against global regulatory and supply constraints, including:

• Pharmacopoeial compliance.
• Nitrosamine and elemental impurity risk.
• Residual solvent controls.
• Animal-origin-free status.
• TSE/BSE documentation.
• Regional colorant restrictions.
• Availability from multiple qualified suppliers.

How does prucalopride compare with competing constipation drugs?

Prucalopride competes with osmotic laxatives, stimulant laxatives, secretagogues, and chloride-channel activators. Its primary differentiation is selective prokinetic activity rather than direct water secretion into the intestinal lumen.

Product class	Examples	Prescription status	Excipient opportunity
5-HT4 agonist	Prucalopride	Prescription	Low-dose tablet, ODT, pediatric liquid
GC-C agonist	Linaclotide, plecanatide	Prescription	Capsule stability, bead or tablet systems
Chloride-channel activator	Lubiprostone	Prescription	Softgel and liquid-fill systems
Osmotic laxative	Polyethylene glycol	OTC or prescription	Powder palatability and sachets
Stimulant laxative	Bisacodyl, senna	OTC	Coating, enteric release, chewables

Prucalopride has a formulation advantage because it is already delivered in a simple once-daily tablet. That lowers development risk but also limits the defensibility of routine excipient substitution.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barrier is low-dose blend uniformity rather than difficult active-ingredient release. Developers should control:

• Active particle-size distribution.
• Electrostatic behavior.
• Blend segregation.
• Sampling representativeness.
• Tablet weight variation.
• Magnesium stearate over-lubrication.
• Film-coat weight gain.
• Moisture exposure during granulation and coating.

A process patent is more credible when it ties defined operating parameters to a reproducible technical result. Examples include reduced assay variability, improved dissolution after scale-up, or reduced degradation under accelerated stability conditions.

The active ingredient and succinate salt should be evaluated separately in freedom-to-operate work. Salt, polymorph, crystalline-form, particle-size, manufacturing-process, formulation, and method-of-use claims can create different risk profiles. A generic applicant should not assume that expiry of a compound patent eliminates formulation or process risk.

What is the generic launch outlook for prucalopride?

The most probable launch sequence is:

1. Standard 1 mg and 2 mg immediate-release tablets through the ANDA pathway.
2. Price competition after the initial generic entrants establish supply.
3. Private-label or authorized-generic arrangements.
4. Differentiated lactose-free or excipient-controlled products.
5. ODT, pediatric, or sprinkle products through a 505(b)(2) strategy if market size supports clinical and regulatory investment.

The highest-value opportunity is a differentiated product launched before the market becomes crowded, particularly an ODT or pediatric formulation with meaningful patient-use data. A routine tablet copy can be commercially viable, but its value will depend on manufacturing cost, launch timing, and patent litigation exposure.

Key Takeaways

• Prucalopride succinate is a small-molecule prescription drug with no biosimilar risk.
• The reference products use conventional immediate-release film-coated tablets and include lactose-based excipient systems.
• A lactose-free direct-compression formulation is the lowest-risk differentiation strategy.
• ODT, pediatric liquid, sprinkle, and multiparticulate products offer stronger commercial and patent opportunities.
• Low-dose content uniformity, segregation control, dissolution, and taste are the main formulation challenges.
• U.S. generic competition is governed by ANDA requirements, Orange Book listings, Paragraph IV certifications, and any associated litigation.
• A conventional excipient substitution is unlikely to support strong patent protection without a demonstrated technical effect.
• The most defensible formulation patents would cover defined composition ranges linked to stability, dissolution, palatability, or manufacturing performance.

FAQs

Can prucalopride succinate be formulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler system. The replacement must preserve blend uniformity, tablet strength, disintegration, dissolution, and stability.

Is prucalopride a candidate for an orally disintegrating tablet?

Yes. Its low dose is compatible with ODT development, but taste masking, rapid disintegration, friability, and content uniformity must be controlled.

Would a lactose-free prucalopride tablet receive new FDA exclusivity?

Usually not by itself. A lactose-free composition may support patent claims if it produces an unexpected technical result, but routine excipient substitution generally does not create independent regulatory exclusivity.

Is a prucalopride liquid formulation commercially attractive?

Potentially. A liquid could target pediatric, geriatric, and dysphagic patients, but development requires stability, preservative, palatability, dosing-accuracy, and regulatory work beyond a standard ANDA tablet.

Does prucalopride face biosimilar competition?

No. Prucalopride is a chemically synthesized small molecule. Competition would arise through generic drugs and potentially 505(b)(2) products, not biosimilars.

References

1. U.S. Food and Drug Administration. (2018). Motegrity (prucalopride) prescribing information.
2. European Medicines Agency. (2023). Resolor: EPAR product information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and patent certification requirements.